Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Rubius Therapeutics, Inc is a biotechnology business based in the US. Rubius Therapeutics shares (RUBY) are listed on the NASDAQ and all prices are listed in US Dollars. Rubius Therapeutics employs 197 staff and has a market cap (total outstanding shares value) of USD$519.5 million.
Since the stock market crash in March caused by coronavirus, Rubius Therapeutics's share price has had significant negative movement.
Its last market close was USD$5.01, which is 42.28% down on its pre-crash value of USD$8.68 and 49.55% up on the lowest point reached during the March crash when the shares fell as low as USD$3.35.
If you had bought USD$1,000 worth of Rubius Therapeutics shares at the start of February 2020, those shares would have been worth USD$511.14 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$637.02.
|Latest market close||USD$5.01|
|52-week range||USD$3.35 - USD$14.44|
|50-day moving average||USD$5.0356|
|200-day moving average||USD$5.494|
|Wall St. target price||USD$10.67|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.696|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-16)||N/A|
|1 month (2020-10-27)||7.74%|
|3 months (2020-08-23)||N/A|
|6 months (2020-05-23)||N/A|
|1 year (2019-11-23)||N/A|
|2 years (2018-11-23)||N/A|
|3 years (2017-11-23)||N/A|
|5 years (2015-11-23)||N/A|
|Gross profit TTM||USD$0|
|Return on assets TTM||-28.9%|
|Return on equity TTM||-71.46%|
|Market capitalisation||USD$519.5 million|
TTM: trailing 12 months
There are currently 8.6 million Rubius Therapeutics shares held short by investors – that's known as Rubius Therapeutics's "short interest". This figure is 2.9% up from 8.4 million last month.
There are a few different ways that this level of interest in shorting Rubius Therapeutics shares can be evaluated.
Rubius Therapeutics's "short interest ratio" (SIR) is the quantity of Rubius Therapeutics shares currently shorted divided by the average quantity of Rubius Therapeutics shares traded daily (recently around 178026.01777227). Rubius Therapeutics's SIR currently stands at 48.39. In other words for every 100,000 Rubius Therapeutics shares traded daily on the market, roughly 48390 shares are currently held short.
However Rubius Therapeutics's short interest can also be evaluated against the total number of Rubius Therapeutics shares, or, against the total number of tradable Rubius Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Rubius Therapeutics's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 Rubius Therapeutics shares in existence, roughly 110 shares are currently held short) or 0.3211% of the tradable shares (for every 100,000 tradable Rubius Therapeutics shares, roughly 321 shares are currently held short).
A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against Rubius Therapeutics.
Find out more about how you can short Rubius Therapeutics stock.
We're not expecting Rubius Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Rubius Therapeutics's shares have ranged in value from as little as $3.35 up to $14.44. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Rubius Therapeutics's is 2.0019. This would suggest that Rubius Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Rubius Therapeutics, Inc. focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematological cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.